The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Updates from studies using CLL mouse models
Elisa ten Hacken, PhD, Harvard Medical School, Boston, MA, discusses exciting updates from studies employing genetic engineering in mouse models of chronic lymphocytic leukemia (CLL), focusing on B-cell deprived controlled systems. Dr ten Hacken describes a study assessing how IKZF3 mutation affects cellular fitness during ibrutinib treatment. Other mutations currently being investigated in mouse models include those in the ribosomal proteins RPS15 and Cp53. The use of mouse models allows us to explore how different mutations affect disease outcomes and how they can be targeted therapeutically. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
